Nifuratel is a drug used in gynecology. It is a local antiprotozoal and antifungal agent that may also be given orally. Nifuratel is not approved for use in the United States. It is formulated primarily for intravaginal use as tablets or pessaries and in some markets as oral tablets; the active substance exhibits selective activity against Trichomonas vaginalis, certain Candida species and mixed vaginal infections. Mechanistically it is thought to interfere with protozoal and fungal metabolic pathways and membrane function leading to parasiticidal and fungistatic effects, with limited systemic absorption when administered locally. Typical product development notes include compatibility with common excipients for vaginal delivery, stability under controlled humidity and temperature conditions, and analytical control using HPLC with UV or LC-MS detection for assay and related-substance profiling.
Parent: Nifuratel
Manufacturers and quality control laboratories monitor related substances and degradation products for nifuratel in accordance with ICH Q3A/Q3B principles and product-specific specifications; typical controls include limits for individual specified impurities in the range of 0.1 to 0.5 percent by weight and a total impurity limit commonly set at or below 1.0 percent by weight, with unspecified impurities often set at a more stringent 0.1 percent threshold depending on toxicity data. Classes of impurities that are routinely screened include nitro-reduction products, ring-opened or hydrolytic furan derivatives, N-oxide and dealkylation products, plus residual solvents evaluated by GC. Genotoxic or potentially mutagenic species are assessed against ICH M7 guidance and controlled to levels consistent with the threshold of toxicological concern, which for many small-molecule oral doses corresponds to low microgram per day exposure and typically results in analytical limits in the low 0.01 to 0.05 percent range for those specific impurities. Analytical methods used for release and stability testing include validated HPLC-UV for assay and related substances, LC-MS for impurity identification, and GC for residual solvents.
Nifuratel is used primarily in gynecology to treat local vaginal infections, including trichomoniasis, certain cases of candidiasis and mixed vaginitis; formulations and labeled indications vary by country.
When used as indicated and under medical supervision, topical vaginal nifuratel has an established tolerability profile in countries where it is marketed; common adverse effects are local irritation or hypersensitivity reactions. Safety in pregnancy, lactation and in systemic use should follow local product labeling and prescriber assessment. Nifuratel is not approved in the United States.
Macmiror Complex is a branded combination product that pairs nifuratel with nystatin for local treatment of vaginal infections; it is not a systemic antibiotic in the traditional sense but a topical antiprotozoal and antifungal combination intended to address protozoa and fungal pathogens concurrently.
Nimorazole is marketed under various trade names in different countries; specific brand names depend on the manufacturer and region, so consult local formularies or regulatory resources to identify the marketed brands in your country.
